Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ANG-003 by Anagram Therapeutics for Exocrine Pancreatic Insufficiency: Likelihood of Approval
ANG-003 is under clinical development by Anagram Therapeutics and currently in Phase I for Exocrine Pancreatic Insufficiency. According to GlobalData,...